Follow-up of patients with mycosis fungoides after interferon α2b treatment failure

Introduction Treatment of T cell cutaneous lymphoma( CTCL) is a controversial subject and the effectiveness of treatment is still low. Aim Report of single center experience of management CTCL after progression after first line treatment. Material and methods We present 41 patients with CTCL, 29 received interferon α2b in first line, and 12 of them received second line therapy. Results Overall response rate for second line therapy was 60%. Conclusions Results of the follow-up of patients with mycosis fungoides after interferon α2b treatment failure with the literature review and discussion.

[1]  T. Piotrowski,et al.  Total skin electron irradiation techniques: a review , 2013, Postepy dermatologii i alergologii.

[2]  M. Sokołowska-Wojdyło,et al.  Oral retinoids and rexinoids in cutaneous T-cell lymphomas , 2013, Postepy dermatologii i alergologii.

[3]  B. Coiffier,et al.  Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study. , 2012, Clinical lymphoma, myeloma & leukemia.

[4]  J. Chu,et al.  Mycosis fungoides stage IB progressing to cutaneous tumors. , 2011, Dermatology online journal.

[5]  T. Kuzel,et al.  Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma , 2011, Leukemia & lymphoma.

[6]  A. Rademaker,et al.  Multicenter Phase II Trial of Temozolomide in Mycosis Fungoides/Sézary Syndrome: Correlation with O6-Methylguanine-DNA Methyltransferase and Mismatch Repair Proteins , 2011, Clinical Cancer Research.

[7]  N. Riaz,et al.  The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides. , 2011, Archives of dermatology.

[8]  F. Trautinger.  Phototherapy of mycosis fungoides , 2011, Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia.

[9]  K. Savage,et al.  Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Á. Palomo-Arellano,et al.  Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox , 2011, Case Reports in Dermatology.

[11]  T. Kuzel,et al.  Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. , 2010, Journal of the American Academy of Dermatology.

[12]  J. Becker,et al.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  N. Schmitz,et al.  Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  F. d'Amore,et al.  Phase II trial of zanolimumab (HuMax‐CD4) in relapsed or refractory non‐cutaneous peripheral T cell lymphoma , 2010, British journal of haematology.

[15]  L. F. Glass,et al.  The role of maintenance phototherapy in cutaneous T-cell lymphoma. , 2010, Journal of drugs in dermatology : JDD.

[16]  J. Kolesar,et al.  Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[17]  J. Walewski,et al.  Leczenie pierwotnych chłoniaków skóry. Rekomendacje Sekcji Chłoniaków Skóry Polskiej Grupy Badawczej Chłoniaków (PLRG) The treatment of primary cutaneous lymphoma. Recommendations of the Polish Lymphoma Research Group (PLRG) , 2010 .

[18]  L. Specht,et al.  Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  W. Sterry,et al.  Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Whittaker,et al.  How I treat mycosis fungoides and Sézary syndrome. , 2009, Blood.

[21]  S. Steinberg,et al.  Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  E. Bisaccia,et al.  Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T‐cell lymphoma , 2009, The British journal of dermatology.

[23]  L. Wilson,et al.  Patient Perspectives Regarding the Value of Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma/Mycosis Fungoides: A Pilot Study , 2009, American journal of clinical oncology.

[24]  S. Lade,et al.  Extracorporeal photopheresis for the treatment of Sézary syndrome using a novel treatment protocol. , 2008, Journal of the American Academy of Dermatology.

[25]  Gordon K Smyth,et al.  Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma , 2008, Clinical Cancer Research.

[26]  M. Dreyling,et al.  Primary cutaneous lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  N. Schmitz,et al.  Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma , 2008, Bone Marrow Transplantation.

[28]  A. Avilés,et al.  Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. , 2007, Cancer biotherapy & radiopharmaceuticals.

[29]  E. Olsen,et al.  Response to Oral Forodesine in Refractory Cutaneous T-Cell Lymphoma: Interim Results of a Phase I/II Study. , 2007 .

[30]  M. Duvic,et al.  Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma , 2007, Expert opinion on investigational drugs.

[31]  R. Kurzrock,et al.  Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. , 2006, Clinical lymphoma & myeloma.

[32]  Robert Jeraj,et al.  Radiation characteristics of helical tomotherapy. , 2004, Medical physics.

[33]  T. Rockwell Mackie,et al.  Helical Tomotherapy: An Innovative Technology and Approach to Radiation Therapy , 2002, Technology in cancer research & treatment.

[34]  A. Oliven,et al.  Extracorporeal photopheresis: a review. , 2001, Blood reviews.

[35]  M. Duvic,et al.  Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  G. Wood,et al.  Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. , 2001, Archives of dermatology.

[37]  L. Wilson,et al.  Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. , 2000, Journal of the American Academy of Dermatology.

[38]  S. Pileri,et al.  Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  G. Vejlsgaard,et al.  Interferon treatment of cutaneous T‐cell lymphoma , 1993, European journal of haematology.

[40]  P. Gimsing,et al.  Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. , 2009, Expert opinion on investigational drugs.

[41]  M. Baccarani,et al.  Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. , 2005, Haematologica.

[42]  S. E. Whitmore.  Optimizing bexarotene therapy for cutaneous T-cell lymphoma. , 2004, Journal of the American Academy of Dermatology.

[43]  Pierre Morel,et al.  CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[44]  B. Dréno,et al.  Low-dose recombinant interferon-alpha in the treatment of cutaneous T-cell lymphomas. , 1989, The British journal of dermatology.